secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zentalis Pharmaceuticals, Inc. (ZNTL)
CIK:        0001725160
Form:       8-K
Filed at:   2024-05-29T23:59:59+00:00
Accession:  0001725160-24-000120
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Zentalis appoints Luke Walker, M.D. to board, expanding to 7 directors
----------------------------------------------------------------------

- Board increased from 6 to 7 members; Dr. Walker appointed as Class II director effective May 24, 2024.
- Term runs until 2025 annual meeting; Dr. Walker also joins Audit Committee.
- Initial RSU grant of 72,481 shares valued at $850,000, vesting over 3 years.
- Annual retainer for board service $45,000 plus $10,000 for Audit Committee membership.
- Standard indemnification agreement signed; annual equity grants after 6 months service.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1725160/000172516024000120/0001725160-24-000120-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1725160/000172516024000120/zntl-20240524.htm
  HTML page:      https://secwatch.observer/filing/0001725160-24-000120

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer